

Figure 1






The first contribute on the first of the fir

Figure 3

Α

KSY1 HUVE SKIN KS lesion T1 23-1 HUT78

M fit KDR fit KDR fit KDR fit KDR fit KDR fit KDR fit KDR



В





Figure 4



The form their time the sum that the major of the control is the first first the major of the first first the sum that the

Α

VEGF-A					VEGF-B							VEGF-C				
HT-29	ZR-75	Panc-3	Ov a-3	A375		HT-29	ZR-75	Panc-3	Ova-3	A375		HT-29	ZR-75	Panc-3	Ov a-3	A375
1000	- 1				J.				18	/P				, X.		
e la	. A E			i di			1		b.	i.e.s.			e la	e jiri		
				i									i			
		なる ないかん										es.			The state of the s	
	號	1	1				10000	7	J. S.	1				3	3	

В

HT-29

2R-75

Panc-3

Ova-3

A375

HT-29

Panc-3

A375

A375

A375

A375

A STATE OF ALL AND ALL





Figure 6B C D **VEGF AS-1** oligonucleotides В %Cell Growth VEGF AS-3 oligonucleotides \mathbf{C} % Cell Growth VEGF Scrambled oliogonucleotides D % Cell Growth

Concentration (µM)







Figure 7A B C







Figure 7D

Figure 7E








Figure 7F









Figure 9








Figure 10

Marker
No treatment
VEGF AS 0.5 μM
VEGF AS 1 μM
VEGF AS 10 μM





Marker
No treatment
VEGF S 0.5 μM
VEGF S 1 μM
VEGF S 10 μM






В





THE ROOM OF THE PARTY OF THE PA

Figure 13



The safe Lie and the Cal hast that

FIGURE 14

SEC ID NO. 21






FIGURE 15








FIGURE 16




FIGURE 17





FIGURE 18






FIGURE 19






FIGURE 20










FIGURE 21





:::

FIGURE 23

